This article provides an update on our prior analysis of the infliximab litigation involving Janssen Biotech, Inc. (“Janssen”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Inflectra®
-
-
Earlier this month, Janssen Biotech, Inc., a subsidiary of Johnson and Johnson, (“Janssen” or “Plaintiff”) filed a Complaint in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
FDA approved Samsung Bioepis’s Renflexis® (SB2, infliximab-abda) on Friday, April 21, 2017. Renflexis® is the fifth biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]